10:21 AM EST - Satellos Bioscience Inc. : Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy. Satellos Bioscience Inc.
shares T.MSCL are trading up $0.43 at $16.20.
